Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gillian Mitchell

Showing results (71-80 of 112) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical CareElla R Thompson, Simone M Rowley, Na Li, et al.
Familial Cancer|January 27, 2017
Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?Kate A McBride, Mandy L Ballinger, Timothy E Schlub, et al.
Scientific Reports|October 13, 2015
Reevaluation of the BRCA2 truncating allele c.9976A > T (p.Lys3326Ter) in a familial breast cancer contextElla R Thompson, Kylie L Gorringe, Simone M Rowley, et al.
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, Mark Robson, Judy E Garber, et al.
Human Mutation|October 13, 2011
Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patientsElla R Thompson, Samantha E Boyle, Julie Johnson, et al.
Trials|June 22, 2019
Comparing theory and non-theory based implementation approaches to improving referral practices in cancer genetics: a cluster randomised trial protocolApril Morrow, Emily Hogden, Yoon-Jung Kang, et al.
Hereditary Cancer in Clinical Practice|April 10, 2021
Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of adviceBettina Meiser, Rajneesh Kaur, April Morrow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2011
Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancerSusan M Domchek, Gillian Mitchell, Geoffrey J Lindeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationBella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, et al.
European Urology|August 27, 2014
Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosisGail P Risbridger, Renea A Taylor, David Clouston, et al.
Pageof 12

Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical CareElla R Thompson, Simone M Rowley, Na Li, et al.
Familial Cancer|January 27, 2017
Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?Kate A McBride, Mandy L Ballinger, Timothy E Schlub, et al.
Scientific Reports|October 13, 2015
Reevaluation of the BRCA2 truncating allele c.9976A > T (p.Lys3326Ter) in a familial breast cancer contextElla R Thompson, Kylie L Gorringe, Simone M Rowley, et al.
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, Mark Robson, Judy E Garber, et al.
Human Mutation|October 13, 2011
Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patientsElla R Thompson, Samantha E Boyle, Julie Johnson, et al.
Trials|June 22, 2019
Comparing theory and non-theory based implementation approaches to improving referral practices in cancer genetics: a cluster randomised trial protocolApril Morrow, Emily Hogden, Yoon-Jung Kang, et al.
Hereditary Cancer in Clinical Practice|April 10, 2021
Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of adviceBettina Meiser, Rajneesh Kaur, April Morrow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2011
Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancerSusan M Domchek, Gillian Mitchell, Geoffrey J Lindeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationBella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, et al.
European Urology|August 27, 2014
Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosisGail P Risbridger, Renea A Taylor, David Clouston, et al.
Pageof 12